Description
Vasomune is developing a novel first-in-class investigational medicine to treat patients hospitalized with severe COVID-19 disease. The phase 1 study is the first-in-human study designed to demonstrated safety and tolerability of AV-001 in…
Amendment chain · 4 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $1,260,000 at start, $2,849,345 after amendment #3 (+$1,589,345).
- #02020-11-01$1,260,000
- #12021-08-26$2,849,345+$1,589,345
- #22022-01-28$2,849,345
- #32022-04-08$2,849,345
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-11-01(start date) | $1,260,000 | — | Vasomune is developing a novel first-in-class investigational medicine to treat patients hospitalized with sev… |
| #1 amendment | 2021-08-26 | $2,849,345 | +$1,589,345 | Vasomune is developing a novel first-in-class investigational medicine to treat patients hospitalized with sev… |
| #2 amendment | 2022-01-28 | $2,849,345 | +$0 | Vasomune is developing a novel first-in-class investigational medicine to treat patients hospitalized with sev… |
| #3 amendment | 2022-04-08 | $2,849,345 | +$0 | Vasomune is developing a novel first-in-class investigational medicine to treat patients hospitalized with sev… |
Related records · 6
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 833657133)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2020-2021-Q1-951680 | National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program | $71,148 | FY2021 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q4-965762 · retrieved 2026-11-15.